The RAGE signaling in osteoporosis

Area of Science:

• Bone Biology and Disease
• Cell Signaling Pathways
• Molecular Medicine

Background:

• Osteoporosis (OP) is a global health concern due to imbalanced bone remodeling.
• Receptor for advanced glycation end product (RAGE) is implicated in chronic diseases, including OP.
• RAGE activation negatively influences bone remodeling processes.

Purpose of the Study:

• To comprehensively review the structure and biological functions of RAGE.
• To elucidate the role of RAGE signaling in the pathogenesis of osteoporosis.
• To identify RAGE as a potential therapeutic target for OP.

Main Methods:

• Literature review of RAGE structure and function.
• Analysis of RAGE's role in osteoblast and osteoclast biology.
• Synthesis of evidence linking RAGE ligands to OP pathogenesis.

Main Results:

• RAGE ligands (AGEs, S100, Aβ, HMGB1) activate RAGE signaling.
• Activated RAGE negatively regulates osteoblast proliferation and differentiation.
• Activated RAGE positively stimulates osteoclastogenesis.

Conclusions:

• RAGE signaling plays a critical role in the pathogenesis of osteoporosis.
• RAGE is a key mediator of bone loss in OP.
• Targeting RAGE signaling presents a promising therapeutic avenue for osteoporosis treatment.